Journal article
Prostate cancer vaccines: Update on clinical development
OncoImmunology, Vol.2(5), p.e24523
05/01/2013
DOI: 10.4161/onci.24523
PMID: 23762812
Abstract
Prostate cancer is a common malignancy among elderly men and is essentially incurable once it becomes metastatic. Results from clinical trials testing a panel of specific vaccines in patients with castration-resistant prostate cancer (CRPC) suggest that alternative therapies may one day substitute or support the current gold standard (docetaxel plus prednisone). Here, we summarize the results of germane clinical trials completed during the last 12 y and provide updates on some currently ongoing studies. As it stands, prostate cancer vaccines appear to be safe and capable of generating prostate-specific T lymphocyte responses with potential antitumor activity.
Details
- Title: Subtitle
- Prostate cancer vaccines: Update on clinical development
- Creators
- Sean M GearyAliasger K Salem
- Resource Type
- Journal article
- Publication Details
- OncoImmunology, Vol.2(5), p.e24523
- DOI
- 10.4161/onci.24523
- PMID
- 23762812
- NLM abbreviation
- Oncoimmunology
- ISSN
- 2162-402X
- eISSN
- 2162-402X
- Publisher
- Taylor & Francis
- Language
- English
- Date published
- 05/01/2013
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering; Pharmaceutical Sciences and Experimental Therapeutics; Craniofacial Anomalies Research Center; Dental Research; Chemical and Biochemical Engineering
- Record Identifier
- 9983985849002771
Metrics
18 Record Views